Compare TCMD & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TCMD | ZVRA |
|---|---|---|
| Founded | 1995 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 549.2M | 472.9M |
| IPO Year | 2016 | 2015 |
| Metric | TCMD | ZVRA |
|---|---|---|
| Price | $25.15 | $10.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $36.00 | $23.00 |
| AVG Volume (30 Days) | 202.3K | ★ 684.4K |
| Earning Date | 05-04-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 17.14 | ★ 159.21 |
| EPS | 0.82 | ★ 1.35 |
| Revenue | N/A | ★ $106,470,000.00 |
| Revenue This Year | $11.60 | $37.27 |
| Revenue Next Year | $9.14 | $53.42 |
| P/E Ratio | $30.12 | ★ $7.72 |
| Revenue Growth | N/A | ★ 350.91 |
| 52 Week Low | $8.61 | $7.02 |
| 52 Week High | $37.77 | $13.16 |
| Indicator | TCMD | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 43.81 | 62.95 |
| Support Level | $24.54 | $8.20 |
| Resistance Level | $25.42 | $11.19 |
| Average True Range (ATR) | 0.95 | 0.38 |
| MACD | 0.17 | 0.10 |
| Stochastic Oscillator | 58.97 | 80.00 |
Tactile Systems Technology Inc is a medical technology company. The company is engaged in developing and providing medical devices for the treatment of chronic diseases. The firm's proprietary platform flexitouch system, provides a home-based solution for lymphedema patients. The entire system is another home solution for patients with chronic swelling and actitouch system for chronic venous insufficiency patients that may be worn throughout the day.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.